CA2287487A1 - Utilisation des antagonistes du recepteur de nk-1 dans le traitement des troubles alimentaires - Google Patents

Utilisation des antagonistes du recepteur de nk-1 dans le traitement des troubles alimentaires Download PDF

Info

Publication number
CA2287487A1
CA2287487A1 CA002287487A CA2287487A CA2287487A1 CA 2287487 A1 CA2287487 A1 CA 2287487A1 CA 002287487 A CA002287487 A CA 002287487A CA 2287487 A CA2287487 A CA 2287487A CA 2287487 A1 CA2287487 A1 CA 2287487A1
Authority
CA
Canada
Prior art keywords
phenyl
4alkyl
group
6alkyl
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002287487A
Other languages
English (en)
Inventor
Franz Fridolin Hefti
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Organon Pharma UK Ltd
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9708289.5A external-priority patent/GB9708289D0/en
Priority claimed from GBGB9721265.8A external-priority patent/GB9721265D0/en
Application filed by Individual filed Critical Individual
Publication of CA2287487A1 publication Critical patent/CA2287487A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention porte sur l'utilisation d'un antagoniste du récepteur de NK-1, éventuellement avec un agent anorexique, en vue de fabriquer un médicament destiné à être utilisé dans le traitement ou la prévention des troubles alimentaires. L'invention porte également sur des procédés de traitement utilisant l'antagoniste du récepteur de NK-1 et sur des compositions pharmaceutiques et les produits qu'elles contiennent.
CA002287487A 1997-04-24 1998-04-22 Utilisation des antagonistes du recepteur de nk-1 dans le traitement des troubles alimentaires Abandoned CA2287487A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB9708289.5A GB9708289D0 (en) 1997-04-24 1997-04-24 Therapeutic use
GB9708289.5 1997-04-24
GBGB9721265.8A GB9721265D0 (en) 1997-10-07 1997-10-07 Therapeutic use
GB9721265.8 1997-10-07
PCT/GB1998/001161 WO1998047513A1 (fr) 1997-04-24 1998-04-22 Utilisation des antagonistes du recepteur de nk-1 dans le traitement des troubles alimentaires

Publications (1)

Publication Number Publication Date
CA2287487A1 true CA2287487A1 (fr) 1998-10-29

Family

ID=26311439

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002287487A Abandoned CA2287487A1 (fr) 1997-04-24 1998-04-22 Utilisation des antagonistes du recepteur de nk-1 dans le traitement des troubles alimentaires

Country Status (5)

Country Link
EP (1) EP0977572A1 (fr)
JP (1) JP2001524960A (fr)
AU (1) AU744261B2 (fr)
CA (1) CA2287487A1 (fr)
WO (1) WO1998047513A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU773188C (en) * 1999-03-19 2006-01-05 Abbott Gmbh & Co. Kg Method of treating eating disorders
EP1220673A2 (fr) * 1999-10-13 2002-07-10 Glaxo Group Limited Methode destinee au traitement de l'obesite
CN100537527C (zh) * 2001-03-21 2009-09-09 法马科皮亚公司 具有mch调节活性的芳基和二芳基化合物
DE10311984A1 (de) * 2003-03-12 2004-09-23 Freie Universität Berlin Verwendung von NEP-assoziierten Molekülen zur Behandlung von nichtimmunogenen-nichthypertensiven Zivilisationskrankheiten
CN106290894A (zh) * 2016-07-21 2017-01-04 浙江理工大学 一种基于nk1r蛋白的白血病检测试剂盒

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8929070D0 (en) * 1989-12-22 1990-02-28 Fujisawa Pharmaceutical Co Peptide compounds,processes for preparation thereof and pharmaceutical composition comprising the same
UA41251C2 (uk) * 1990-01-04 2001-09-17 Пфайзер, Інк. Гідровані азотвмісні гетероциклічні сполуки, похідні піперидину, фармацевтична композиція та спосіб пригнічення активності речовини р в організмі
CZ293955B6 (cs) * 1991-03-26 2004-08-18 Pfizeráinc Postup přípravy substituovaných piperidinů
MY110227A (en) * 1991-08-12 1998-03-31 Ciba Geigy Ag 1-acylpiperindine compounds.
FR2689888B1 (fr) * 1992-04-10 1994-06-10 Rhone Poulenc Rorer Sa Nouveaux derives de perhydroisoindole, leur preparation et les compositions pharmaceutiques qui les contiennent.
IL106142A (en) * 1992-06-29 1997-03-18 Merck & Co Inc Morpholine and thiomorpholine tachykinin receptor antagonists, their preparation and pharmaceutical compositions containing them
FR2696178B1 (fr) * 1992-09-30 1994-12-30 Sanofi Elf Amides basiques quaternaires, procédé pour leur préparation et compositions pharmaceutiques en contenant.
IS4208A (is) * 1993-09-22 1995-03-23 Glaxo Group Limited 3-(tetrazólýl-benzyl)amínó-piperadidín afleiður
US6403577B1 (en) * 1993-11-17 2002-06-11 Eli Lilly And Company Hexamethyleneiminyl tachykinin receptor antagonists
EP1462450B1 (fr) * 1993-12-29 2007-06-13 MERCK SHARP & DOHME LTD. Dérivés de morpholine substitués et leur application en tant qu'agents thérapeutiques
TW385308B (en) * 1994-03-04 2000-03-21 Merck & Co Inc Prodrugs of morpholine tachykinin receptor antagonists
AU691327B2 (en) * 1994-08-15 1998-05-14 Merck Sharp & Dohme Limited Morpholine derivatives and their use as therapeutic agents
WO1996024353A1 (fr) * 1995-02-10 1996-08-15 Eli Lilly And Company Procede de traitement ou de prevention de troubles psychiatriques
EP0839043A2 (fr) * 1995-05-25 1998-05-06 BioFrontiers, Inc. Compositions pharmaceutiques contenant du sulfate de calcium
CA2203424A1 (fr) * 1995-08-21 1997-02-27 Eli Lilly And Company 2-acylaminopropanamines servant de secretagogues de la somatotrophine
AU2611297A (en) * 1996-04-12 1997-11-07 Eli Lilly And Company Bisindoles for treating pain or nociception
KR20000022060A (ko) * 1996-06-21 2000-04-25 더블유. 지. 콜 스피로-피페리딘 유도체 및 치료제로서의 이의 용도
GB9613969D0 (en) * 1996-07-03 1996-09-04 Merck Sharp & Dohme Therapeutic agents

Also Published As

Publication number Publication date
AU744261B2 (en) 2002-02-21
AU7065798A (en) 1998-11-13
JP2001524960A (ja) 2001-12-04
EP0977572A1 (fr) 2000-02-09
WO1998047513A1 (fr) 1998-10-29

Similar Documents

Publication Publication Date Title
AU735760B2 (en) Use of a NK-1 receptor antagonist and an SSRI for treating obesity
US6232311B1 (en) Method for treating or preventing psychosomatic and psychoimmunologic disorders
CA2266773A1 (fr) Utilisation de l'antagoniste du recepteur nk-1 utilise comme antidepresseur et/ou agent anxiolytique
CA2287487A1 (fr) Utilisation des antagonistes du recepteur de nk-1 dans le traitement des troubles alimentaires
US5952330A (en) Use of NK-1 receptor antagonists for treating mania
AU4279699A (en) Use of a nk-1 receptor antagonist for treating psychiatric disorders
AU749976B2 (en) Method for treating premenstrual or late luteal phase syndrome
AU745524B2 (en) Method for treating attention deficit disorder
AU738047B2 (en) Use of NK-1 receptor antagonists for treating mania
AU4279599A (en) Use of an nk-1 receptor antagonist for treating cognitive disorders
AU737019B2 (en) Use of NK-1 receptor antagonists for treating aggressive behaviour disorders
WO1999027938A1 (fr) Methode de traitement ou de prevention de troubles psychosomatiques et psycho-immunologiques
CA2334607A1 (fr) Utilisation d'un antagoniste du recepteur nk-1 pour le traitement de dysfonctionnements sexuels
WO1999007374A1 (fr) Utilisation d'antagonistes de recepteur de nk-1 dans le traitement du comportement agressif
JP2001513500A (ja) 躁病の治療のためのｎｋ−１受容体拮抗薬の使用
EP1001780A1 (fr) Utilisation d'antagonistes du recepteur nk-1 pour le traitement d'une manie

Legal Events

Date Code Title Description
FZDE Dead